In a study in South Africa, women felt stigma around taking daily PrEP pills, leading to low adherence. Lenacapavir injection in the PURPOSE 1 trial effectively prevented HIV transmission, prompting a shift in prevention strategy.
The trial involving 5,300 women in South Africa and Uganda showed zero HIV infections in those receiving lenacapavir injections, while participants on oral PrEP experienced a 2% infection rate, aligning with previous clinical trials data.
Collection
[
|
...
]